J&J sees 'evolution in pricing, not a revolution' in 2019

"I think we just need to be careful; things such as list price alone [are] not the full extent of the information," said J&J's pharma unit chief on a Tuesday call.

By Jacob Bell • Oct. 16, 2018

5 questions on the Trump admin's bid to mandate prices in drug ads

Pharma, which spends billions each year to advertise its products on television, is expected to fiercely oppose the proposal.

By Ned Pagliarulo , Andrew Dunn • Oct. 16, 2018

Confronting pharma, Trump admin seeks price disclosure in drug ads

HHS chief Alex Azar announced the much-anticipated proposal Monday, dismissing a new pledge from trade lobby PhRMA as insufficient.

By Ned Pagliarulo , Andrew Dunn • Updated Oct. 15, 2018

Under pressure, drugmakers give an inch on DTC drug ads

Members of the trade group PhRMA will soon point consumers to drug cost information in direct-to-consumer TV ads, but won't go so far as to include prices upfront.

By Ned Pagliarulo • Updated Oct. 15, 2018

Gilenya beats Copaxone head-to-head at higher dose, study finds

The multiple sclerosis drugs are top-sellers for their respective makers, Novartis and Teva. Yet a Phase 3b trial showed an efficacy edge for Gilenya.

By Andrew Dunn • Oct. 11, 2018

Price increases on top drugs drove majority of recent growth, analysis finds

Over the past three years, roughly 60% of the growth in U.S. sales for four dozen top-selling drugs came via price increases, according to numbers crunched by investment firm Leerink.

By Ned Pagliarulo • Oct. 10, 2018